052 vs P = 0 073) Nevertheless, the results tend to migrate to

052 vs. P = 0.073). Nevertheless, the results tend to migrate to statistical significant Fludarabine directions accompanied extension of follow-up time and expansion of sample size. In addition, as the gene sensitive to cisplatin or other DNA damaging agents, expression of ERCC1 is closely related to BRCA1, no matter in breast cancer or in NSCLC [29, 30]. But there is not much more studies indicate correlations between BAG-1. Our findings demonstrate a strong correlation between ERCC1 and BAG-1. Therefore, it is plausible that patients with the expression of ERCC1 and

BAG-1 present a poor prognosis and the lack of its expression would receive more benefit from non platinum based chemotherapy. As one of the targets of gemcitabine, RRM1 also have roles in DNA repair systems like ERCC1 and BRCA1. It encodes the regulatory subunit of ribonucleotide reduction of ribonucleoside diphosphates to the corresponding deoxyribonucleotides [31]. In earlier study,

it suggested continuous exposure of lung cancer cell lines to increasing amounts of Everolimus gemcitabine resulted in increased expression of RRM1 [32]. In addition, another research showed reduced RRM1 expression increased sensitivity to gemcitabine in lung cancer cell lines, and found RRM1 expression LY3039478 concentration in tumor is a major predictor of disease response to gemcitabine chemotherapy during a prospective phaseII clinical trial with NSCLC [8]. TUBB3 is investigated and recognized as a role in resistance to antitubulin agents. The report shows TUBB3 is expressed in high levels in lung cancer cell lines, and by using RNAi technology, it was found that TUBB3 mediates sensitivity to paclitaxel in NSCLC cells, and high levels of TUBB3 expression are associated with paclitaxel and docetaxel resistance in vitro [11, 33, 34]. Our result showed that TUBB3 was more frequently observed in stage I + II than in stage III + IV patients (P = 0.004). But Recent data suggested expression of TUBB3 was related to advanced stage NSCLC [35]. In this study, no correlation of chemotherapy between RRM1 and TUBB3, or the

survival of the patients was found. It might be caused by the limitation of different cycles of adjuvant chemotherapy taken by patients and Dehydratase other interferences like number of samples and only one clinical center involved in our study. Conclusions In summary, to better overcome the problems related to drug resistance and to improve the clinical outcome of advanced NSCLC patients, relationship between drug resistance caused by gene expression and prognosis of patients received adjuvant chemotherapy must be investigated. Our findings indicate ERCC1 and BAG-1 are prognostic factors for progression-free and overall survival, and may be predictive biomarkers for platinum based chemotherapy in NSCLC patients. Accompanied by enlargement of sample size, BRCA1 might also be an indicator the above-mentioned.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>